INTRODUCTION
Elevated triglycerides (TG) along with elevated low density lipoprotein cholesterol (LDL-C) and reduced high density lipoprotein cholesterol (HDL-C) are consistent with the lipoprotein phenotype observed in mixed (or combined) hyperlipidemia. As more data accrues in this area, it is apparent that individuals displaying these lipid characteristics also generally exhibit a preponderance of smaller, more dense LDL particles, which correlates with the high-risk LDL subclass pattern B phenotype. These lipoprotein changes and the associated particle size distribution have been shown to be altered to greater degree in patients with established cardiovascular disease (CVD) or in patients at high risk for a coronary event. (1) (2) (3) (4) (5) (6) Large clinical trials focusing on serum lipid changes and their relationship to risk reduction, have observed treatment effects on CHD risk that were greater than expected from the changes in traditional lipid parameters such as total plasma cholesterol and triglycerides. Patients with the lipid triad (elevated LDL-C and TG and low HDL-C levels) are at greater risk for coronary heart disease (CHD) than the general population, and they benefit from treatment with simvastatin (7) or fibrate. (8,9) Therefore, changes in lipoprotein subclasses and particle size may contribute to these beneficial outcomes. Unfortunately, there are limited data to date specifically comparing on-treatment changes in lipoprotein subclasses with reduction in risk for CHD events. (5) employed in the treatment of mixed hyperlipidemia and have been shown to lower TG by 20-50% and LDL-C by 5-20%, and to raise HDL-C by 10-20% (11) This could be attributed mainly to the effect of ezetimibe/simvastatin as there was little or no incremental LDL-C reduction from baseline observed for the addition of fenofibrate. (16) Similarly, the change in HDL-C could be attributed mainly to fenofibrate as there was little or no incremental change in the combination treatment compared to those observed for fenofibrate alone.
The effect of ezetimibe/simvastatin + fenofibrate on non-HDL, Apo B and TG were significantly greater for the combination than for either treatment alone raising the possibility that their effects may be complementary or overlap in pathways affecting these parameters, resulting in an effect that was less than additive when compared to the sum of the results for the separate treatments.
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In addition, and consistent with the well-known effects of fenofibrate on plasma TG, VLDL-C and LDL-C subclass distributions, nearly 66% of the patients on either ezetimibe/simvastatin + fenofibrate or fenofibrate alone had a larger, more buoyant LD-C subclass pattern compared to fewer than 20% at baseline. (16) The purpose of the analysis presented here was to evaluate the effects of ezetimibe/simvastatin and fenofibrate both as monotherapy and in coadministration in more detail by examining their effects on individual lipoprotein subclasses using the VAP II and S 3 GGE™ methods in patients with mixed hyperlipidemia.
DESIGN and METHODS
The complete details of study design and patient entry criteria are published elsewhere. (16) In brief, this was a multicenter, international, randomized, double-blind, placebo-controlled, parallel group study. The study was approved by local investigation review boards and all patients provided written informed consent. Eligible patients were men and women aged 18 to 79 years with mixed hyperlipidemia and no coronary heart disease (CHD), CHD-equivalent disease (except for type 2 diabetes), or CHD risk score >20% as defined by NCEP ATP III.
After drug washout and a run-in period with a lipid-altering diet and placebo study drug, lipid criteria for randomization were LDL-C 130 to 220 mg/dL inclusive and TG 150 to 500 mg/dL 
Statistical Analysis
Endpoints in this exploratory analysis included percent change from baseline to study endpoint in cholesterol associated with individual lipoprotein subfractions including VLDL-C 1+2 and VLDL-C 3, IDL-C, LDL-C 1 to 4, Lp(a), and HDL-C 2 and HDL-C 3 and changes in LDL particle size. A modified intention-to-treat approach was used with all randomized patients who had baseline values, had taken at least one dose of study medication, and had at least one postbaseline measurement. An analysis-of-covariance (ANCOVA) model with terms for treatment (placebo, ezetimibe/simvastatin, fenofibrate, ezetimibe/simvastatin + fenofibrate) and baseline TG was used to compare each efficacy parameter. For data not normally distributed, e.g., TG, a nonparametric test (ANCOVA model based on Tukey's normalized ranks) was used for inferential testing of between-treatment differences. Change data were expressed as mean or median percent change (95% confidence interval). Hodges-Lehmann estimates of the median difference between treatments with a corresponding distribution-free confidence interval based on Wilcoxon's rank sum test were used to determine the CI for median data.
RESULTS

Baseline Characteristics
The treatment groups were generally well-matched with respect to baseline demographics and (Table 1) . Among the LDL-C subfractions, LDL-C 4 exhibited the lowest mass and LDL-C 3 exhibited the greatest mass (accounting for about 12% and 63%, respectively, of the total LDL-C subfraction mass) in all four treatment groups. The baseline values for LDL-CR were approximately 30 mg/dL lower than the LDL-C value determined following preparative ultracentrifugation due to the lack of inclusion of cholesterol associated with IDL and Lp(a).
Importantly, although LDL-CR values were lower, they were highly correlated with standard LDL-C values.
Treatment-induced changes in lipoprotein subfractions
Median percent changes from baseline to study endpoint for VLDL-C, IDL-C, and LDL-CR are shown in Figure 1 . Relative to placebo, ezetimibe/simvastatin, fenofibrate, and ezetimibe/simvastatin + fenofibrate significantly reduced cholesterol mass in all of these lipoprotein classes. With both ezetimibe/simvastatin and ezetimibe/simvastatin + fenofibrate, the most pronounced (percent) changes were observed for IDL-C. The effects of ezetimibe/simvastatin, fenofibrate, and ezetimibe/simvastatin + fenofibrate on VLDL subclasses ( Figure 2 ) were similar in pattern to those for VLDL-C overall ( Figure 1) ; effects for all treatments appeared to be slightly more pronounced for VLDL-C 1+2 than for VLDL-C 3.
Although the changes in VLDL-C are approximately the same for either ezetimibe/simvastatin and for fenofibrate alone, co-administration demonstrates an increased effect that is less than expected from the sum of each of the treatments. The changes in IDL-C are essentially maximized by ezetimibe/simvastatin with little additional effect of fenofibrate.
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The modest 10% reduction in LDL-CR with fenofibrate treatment (Figure 1 ) was accounted for by reductions in LDL-C 1, LDL-C 3 and LDL-C 4 which are respectively the most buoyant, the second most dense and most dense subfractions (Figure 3 ) offset by the highly significant 66% increase in LDL-C 2, the second most buoyant of the LDL fractions. Significant reductions were observed for all LDL-C subfractions, LDL-C 1, C 2, C 3 and C 4, following ezetimibe/simvastatin treatment.
When coadministered, the distinctive effects of both fenofibrate and ezetimibe/simvastatin were evident. Ezetimibe/simvastatin + fenofibrate produced a pattern of changes similar in direction to those of fenofibrate alone, suggesting that the change in LDL-C pattern was primarily a function of fenofibrate. Coadministration led to greater, but not additive, cholesterol lowering in LDL-C 3, the most abundant LDL-C fraction, whereas treatment with fenofibrate alone gave a greater effect for LDL-C 4. With the exception of LDL-C4, the relative quantitative changes were greatest for either ezetimibe/simvastatin alone or the combination, suggesting this effect is attributable mainly to ezetimibe/simvastatin. Thus, the separate beneficial effects of each therapy were captured in the combination therapy.
Cholesterol associated with Lp(a) was not significantly different from placebo for any of the groups (data not shown). Fenofibrate and ezetimibe/simvastatin + fenofibrate similarly increased median HDL-C 2 and HDL-C 3 compared to ezetimibe/simvastatin or placebo (Figure 4) suggestive that this effect is attributable mainly to fenofibrate. 
Treatment-induced changes in LDL particle size
The size of the predominant LDL peak was similar among the treatment groups at baseline. ezetimibe/simvastatin did not significantly affect LDL particle size, whereas both fenofibrate and ezetimibe/simvastatin + fenofibrate increased LDL particle size ( Table 2) . As previously published, the proportions of patients exhibiting LDL size pattern B at baseline were 64%, 55%, 59%, and 63% in the placebo, ezetimibe/simvastatin, fenofibrate, and ezetimibe/simvastatin + fenofibrate groups, respectively. (16) At study endpoint, the percentages of patients exhibiting LDL size pattern B changed to 64%, 49%, 14%, and 17% in the placebo, ezetimibe/simvastatin, fenofibrate, and ezetimibe/simvastatin + fenofibrate groups, respectively.
DISCUSSION
The interesting finding is that for this combination of therapeutic agents, it appears that the forte of each of the separate therapies was preserved in the case of LDL-C lowering effects for ezetimibe/simvastatin and HDL raising, triglyceride lowering and buoyancy raising effects for fenofibrate. In this set of patients with mixed hyperlipidemia, fenofibrate had only modest effects on overall LDL-C mass, but led to a marked redistribution within LDL subclasses characterized by a loss of mass in the physically smaller, more dense LDL-C 3 and LDL-C 4 subclasses and an increase of mass in the larger, more buoyant LDL-C 2. These results are consistent with previous observations and are attributed to the marked effects of fenofibrate on TG metabolism. On the other hand, ezetimibe/simvastatin therapy produced significant reductions in VLDL-C, IDL-C, and LDL-CR mass compared to placebo. Percent reduction in IDL-C mass was particularly pronounced with ezetimibe/simvastatin. Changes in LDL-CR were observed as reductions in all subclasses (LDL-C 1, C 2, C 3, and C 4) as determined by the VAP II method with the greatest relative change in LDL-C 1 and C 3. The median content of LDL-C 2 was increased by greater than 60% by fenofibrate while this effect was blunted to about a 15% increase by the combination therapy due to the cholesterol lowering effect of ezetimibe/simvastatin when added to fenofibrate. The combination of ezetimibe/simvastatin + fenofibrate resulted in greater effects than either separate therapy on VLDL-C subfractions.
Thus, changes in TG-rich lipoproteins with ezetimibe/simvastatin + fenofibrate were generally greater than for fenofibrate alone, but they did not reach the sum of the separate therapies.
With all therapies added together, the sum of the effects observed on the lipoprotein subclasses when administered separately was not achieved. From the design of the study, the contribution of the ezetimibe with simvastatin and fenofibrate alone to the cholesterol content of the various lipoprotein subfractions has been identified. From a previous study, the combination of ezetimibe and fenofibrate appeared to approach the sum of the individual activities of the individual agents. (15) To determine the fenofibrate related effects when it is administered with simvastatin, it is necessary to extrapolate the effect of fenofibrate alone from other studies (15, 16) and apply it to the previous simvastatin with fenofibrate study (14) , as that study did not have a fenofibrate only arm. The extrapolated results indicate that the use of simvastatin and fenofibrate together appeared not to approach a sum of the separate activities. Therefore, it appears that when simvastatin/ezetimibe is present, the LDL-C reductions seem to be already near maximum, but with an LDL-C subfraction distribution that is characteristic of fenofibrate.
This may indicate that the sum of the mechanisms of action when all three agents are present have reached a saturation of major, perhaps interconnected, pathways for the effect of anyone of the agents.
Treatment with fenofibrate and ezetimibe/simvastatin + fenofibrate increased LDL peak particle size compared to placebo or ezetimibe/simvastatin. For ezetimibe/simvastatin therapy, the increases in LDL peak particle size were modest compared to placebo. These changes in LDL particle size are reflected in the dramatic change from baseline in proportion of patients with LDL size pattern B with fenofibrate and ezetimibe/simvastatin + fenofibrate treatments. (16) These changes are consistent with greater reductions in VLDL-C, IDL-C, and LDL-C 4 and improvements in the mass of the larger, more buoyant LDL-C 2 subfraction observed with fenofibrate and ezetimibe/simvastatin + fenofibrate treatments.
Changes in HDL-C subclasses were primarily influenced by fenofibrate, which is in agreement with those noted for HDL-C and apolipoprotein AI. 
